Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
详细信息 查看全文
- 作者：Daigo Yamamoto ; Nobuaki Sato ; Yoshiaki Rai…
- 关键词：Capecitabine ; Docetaxel ; HER2 ; negative ; Anthracycline ; pretreated ; Metastatic breast cancer
- 刊名：Breast Cancer Research and Treatment
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：161
- 期：3
- 页码：473-482
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Oncology;
- 出版者：Springer US
- ISSN：1573-7217
- 卷排序：161
文摘
PurposeThe randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer.